Phase I/II trial of weekly nab-paclitaxel as second- or third-line treatment in patients with advanced non-small-cell lung cancer(OLCSG1303)
Phase 1
- Conditions
- on-small Cell Lung Cancer
- Registration Number
- JPRN-UMIN000012404
- Lead Sponsor
- Okayama Lung Cancer Study Group (OLCSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
Not provided
Exclusion Criteria
a case who has a history of paclitaxel or nab-paclitaxel treatment. a case with symptom(s) caused by brain metastasis or a case with meningeal dissemination. a case who has treated with thoracic radiotherapy within 4 weeks or radiotherapy for other site(s) within 2 weeks a case who has major concomitant disease as interstitial lung disease, severe cardiac disease(unstable angina pectoris, history of myocardial infarction, uncontrolled arrhythmia, severe diabetes mellitus, active infection, HBV/ HCV hepatitis or liver cirrhosis ) a case who met contraindications on a nab-PTX package leaflet.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective Response Rate
- Secondary Outcome Measures
Name Time Method safety and tolerability profile, progression-free survival, overall survival